CX3CR1 and dilated cardiomyopathy: The evidence base and existing literature suggest that upregulation of fractalkine/CX3CR1, together with CMV seropositivity and consequent migration of immune and inflammatory cells, is associated with worse outcomes in patients with inflammatory conditions including dilated cardiomyopathy.